Once-hurting Pozen Inc. got whopping relief from AstraZeneca plc in the form of a potential $375 million deal, with $40 million up front, to develop fixed-dose combinations of naproxen and AstraZeneca's esomeprazole for chronic pain. (BioWorld Today)